Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 17Liposarcoma 3Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Ovarian Neoplasms 2Leiomyosarcoma 2Breast Neoplasms 2Solitary Fibrous Tumors 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Melanoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Doxorubicin 19Ifosfamide 12Radiotherapy 11pembrolizumab 6Nivolumab 6Ipilimumab 6pazopanib 4Specimen Handling 4Radiation 4Gemcitabine 4Docetaxel 4CTLA-4 Antigen 4Biopsy 4Trabectedin 3Sunitinib 3Magnetic Resonance Spectroscopy 3pegfilgrastim 2liposomal doxorubicin 2cabozantinib 2brostallicin 2X-Rays 2Radiotherapy, Conformal 2Radiation Dose Hypofractionation 2Methotrexate 2Imatinib Mesylate 2Filgrastim 2Etoposide 2Diathermy 2Cisplatin 2Chemotherapy, Adjuvant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytoma, Malignant Fibrous × eribulin × Sarcoma × Clear all
NCT03899805 2025-08-28

A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas

Dana-Farber Cancer Institute

Phase 2 Completed
57 enrolled 14 charts
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡